EW · News · 20260809N
Revenue Performance and Mix
Edwards Lifesciences Corp · 2026-08-09 · Importance 5 · Surprise 6 · In source text
Edwards Lifesciences reported quarterly revenue of $1.74 billion. Quarterly EPS was $0.78, and the company exceeded consensus earnings estimates. The report did not provide year-over-year revenue growth, sequential revenue change, or segment revenue details.
Key facts
- Edwards Lifesciences reported quarterly earnings of $0.78 EPS and $1.74 billion in revenue, beating consensus estimates. source
- Seilern Investment Management Ltd reduced its stake in Edwards Lifesciences by 13% in Q2 2026, selling 89,960 shares. source
- Seilern Investment Management Ltd's position in Edwards Lifesciences represented 6.8% of its portfolio. source
- Analysts maintain a "Moderate Buy" rating on Edwards Lifesciences with an average price target of $100.27 while the company's current share price was $89.65. source
- Edwards Lifesciences remained Seilern Investment Management Ltd's fourth-largest holding. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Edwards Lifesciences reported quarterly earnings of $0.78 EPS and $1.74 billion in revenue, beating consensus estimates. |
| net_income | positive | realized | — | Edwards Lifesciences reported quarterly earnings of $0.78 EPS and $1.74 billion in revenue, beating consensus estimates. |